Search Results

DMOG 200 mg  | Purity Not Available

TargetMol

DMOG, an antagonist of the α-ketoglutarate cofactor, is an inhibitor for HIF prolyl hydroxylase.

More Information Supplier Page

Alectinib 100 mg  | Purity Not Available

TargetMol

CH5424802 is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.

More Information Supplier Page

MHY1485 200 mg  | 97.74%

TargetMol

MHY1485 is a mTOR activator. It inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes, leading to the accumulation of LC3II protein and enlarged autophagosomes.

More Information Supplier Page

MHY1485 25 mg  | 97.74%

TargetMol

MHY1485 is a mTOR activator. It inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes, leading to the accumulation of LC3II protein and enlarged autophagosomes.

More Information Supplier Page

Dabrafenib 200 mg  | Purity Not Available

TargetMol

Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase (IC50s: 0.7/5 nM for B-Raf (V600E)/C-Raf).

More Information Supplier Page

Bikinin 200 mg  | 99.91%

TargetMol

Bikinin, a potent inhibitor of plant GSK-3/Shaggy-like kinase, activates BR signaling downstream of the BR receptor.

More Information Supplier Page

CTX-0294885 2 mg  | 99.95%

TargetMol

CTX-0294885, a novel bisanilino pyrimidine, exhibits inhibitory activity against a broad range of kinases in vitro and is further developed into a Sepharose-supported kinase capture reagent.

More Information Supplier Page

Navitoclax 100 mg  | 98.88%

TargetMol

Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family protein inhibitor that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki < 1 nM for all three proteins).

More Information Supplier Page

APD668 2 mg  | 99.97%

TargetMol

APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119, respectively.

More Information Supplier Page